Traders should monitor FDA review timelines and potential upcoming catalysts, such as priority review designation or PDUFA date announcements. This NDA submission increases the near-term value inflection potential for NUVL stock.
Price Chart
Executive Summary
Nuvalent, Inc. announced the submission of its New Drug Application (NDA) to the U.S. FDA for neladalkib, a treatment for tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. This is a key regulatory milestone in the company's oncology pipeline.
Key Facts
- Nuvalent submitted a New Drug Application (NDA) to the FDA for neladalkib.
- The drug candidate targets advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors.
- The announcement represents a significant advancement in the company's clinical development program.
- No financial figures or timelines for FDA decision were disclosed in the filing.
Financial Impact
Potential future revenue from neladalkib if approved; no specific figures disclosed.
Risk Factors
- FDA may not approve neladalkib or may require additional data.
- Competition from existing and emerging ALK inhibitors could impact market adoption.
- As a clinical-stage biotech, Nuvalent remains subject to high regulatory and development risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001861560-26-000003 |
| Document: 0001861560-26-000003-index-headers.html | 0001861560-26-000003 |
| Document: 0001861560-26-000003-index.html | 0001861560-26-000003 |
| Document: 0001861560-26-000003.txt | 0001861560-26-000003 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 15, 2026 11w ago | 25-NSE | $123.96 $123.96 | · 0.00% | ▲ +0.98% | — |
Jul 15, 2026 11w ago | 8-K | $123.96 $123.96 | · 0.00% | ▲ +0.98% | — |
Jul 8, 2026 12w ago | Insider Cluster | $123.80 $123.96 | ▲ +0.13% | ▼ −0.73% | — |
Jul 6, 2026 12w ago | Insider Cluster | $123.72 $123.90 | ▲ +0.15% | ▼ −0.34% | — |
Jun 11, 2026 16w ago | Insider Cluster | $123.25 $123.43 | ▲ +0.15% | ▼ −0.53% | — |
Jun 10, 2026 16w ago | Insider Cluster | $123.45 $123.36 | ▼ −0.07% | ▼ −0.51% | — |
Jun 9, 2026 16w ago | 8-K | $123.25 $123.35 | ▲ +0.08% | ▼ −2.33% | — |
May 7, 2026 21w ago | 8-K | $102.40 $105.22 | ▲ +2.75% | ▲ +1.25% | — |
Apr 29, 2026 22w ago | Insider Cluster | $99.10 $101.47 | ▲ +2.39% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access